|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-11-25
|
|
pubmed:abstractText |
Based on reported synergy of the topoisomerase-I (topo-I) inhibitor irinotecan with antimetabolites, irinotecan and cytarabine (Ara-C) were administered sequentially to patients with acute myeloid leukemia (AML) refractory to or relapsed following high-dose Ara-C and anthracycline therapy. Pharmacokinetic and pharmacodynamic studies were performed with the first irinotecan dose.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
57
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
73-83
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:16010591-Acute Disease,
pubmed-meshheading:16010591-Adult,
pubmed-meshheading:16010591-Aged,
pubmed-meshheading:16010591-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16010591-Camptothecin,
pubmed-meshheading:16010591-Cytarabine,
pubmed-meshheading:16010591-DNA, Neoplasm,
pubmed-meshheading:16010591-DNA Damage,
pubmed-meshheading:16010591-DNA Topoisomerases, Type I,
pubmed-meshheading:16010591-Dose-Response Relationship, Drug,
pubmed-meshheading:16010591-Drug Synergism,
pubmed-meshheading:16010591-Female,
pubmed-meshheading:16010591-HL-60 Cells,
pubmed-meshheading:16010591-Humans,
pubmed-meshheading:16010591-Leukemia, Myeloid,
pubmed-meshheading:16010591-Male,
pubmed-meshheading:16010591-Middle Aged,
pubmed-meshheading:16010591-Recurrence
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia.
|
|
pubmed:affiliation |
Leukemia Section, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. hans.minderman@roswellpark.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
